N-terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], aid differentiation of E75-TCR+CD8+ cells to perforin-positive cells

DSpace/Manakin Repository

Show simple item record

dc.contributor.author Matsueda, S en
dc.contributor.author Gao, H en
dc.contributor.author Efferson, CL en
dc.contributor.author Tsuda, N en
dc.contributor.author Ishiyama, S en
dc.contributor.author Li, Y en
dc.contributor.author Ioannides, MG en
dc.contributor.author Fisk, B en
dc.contributor.author Peoples, GE en
dc.contributor.author Ioannides, CG en
dc.date.accessioned 2014-03-01T01:58:47Z
dc.date.available 2014-03-01T01:58:47Z
dc.date.issued 2009 en
dc.identifier.issn 02507005 en
dc.identifier.uri http://hdl.handle.net/123456789/28723
dc.relation.uri http://www.scopus.com/inward/record.url?eid=2-s2.0-69249191545&partnerID=40&md5=8a54341cc83c528220bf2b0755761e87 en
dc.subject AE-37 en
dc.subject AE-47 en
dc.subject Cancer vaccines en
dc.subject E75 en
dc.subject F7 en
dc.subject Helper effect en
dc.subject HER-2 en
dc.subject High-affinity CD8+ cells en
dc.subject p776 en
dc.subject Perforin en
dc.subject.other cancer vaccine en
dc.subject.other CD8 antigen en
dc.subject.other cell protein en
dc.subject.other epidermal growth factor receptor 2 en
dc.subject.other gamma interferon en
dc.subject.other peptide en
dc.subject.other peptide ae 37 en
dc.subject.other peptide ae 47 en
dc.subject.other perforin en
dc.subject.other protein e75 en
dc.subject.other protein lrmk en
dc.subject.other T lymphocyte receptor en
dc.subject.other unclassified drug en
dc.subject.other article en
dc.subject.other breast cancer en
dc.subject.other case report en
dc.subject.other cell differentiation en
dc.subject.other controlled study en
dc.subject.other cytotoxic lymphocyte en
dc.subject.other human en
dc.subject.other immunogenicity en
dc.subject.other peripheral blood mononuclear cell en
dc.subject.other priority journal en
dc.subject.other protein expression en
dc.subject.other CD8-Positive T-Lymphocytes en
dc.subject.other Cell Differentiation en
dc.subject.other Enzyme-Linked Immunosorbent Assay en
dc.subject.other Humans en
dc.subject.other Lymphocyte Activation en
dc.subject.other Peptide Fragments en
dc.subject.other Perforin en
dc.subject.other Receptor, erbB-2 en
dc.subject.other Receptors, Antigen, T-Cell en
dc.title N-terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], aid differentiation of E75-TCR+CD8+ cells to perforin-positive cells en
heal.type journalArticle en
heal.publicationDate 2009 en
heal.abstract The objective of this study was to discover whether the peptides LRMK and LRMK-Ava linked to the N-terminus of peptides HER-2 (774-788) and HER-2 (776-788), respectively, help differentiation of E75-TCR+CD8+ cells. Activation was quantified in terms of proliferation of E75-TCR+CD8+ cells expressing high, medium and low density amounts of the specific TCR. Differentiation to functional CD8+ cells was quantified as induction of Perforin (Perf), the lytic-enzyme which mediates the effector function of CD8+ cells, in E75-TCR+CD8+ cells. Peripheral blood mononuclear cells (PBMCs) of 3 patients activated with E75+AE-37 and E75+AE-47 more greatly increased the number of E75-TCRHi CD8+Perf+ cells than PBMCs activated by AE-47 alone or AE-47+ E75. E75 plus cytokines and cytokines alone activated more E75-TCRLow cells than did AE-37 and AE-47. E75+ AE-37 and AE-37 also induced differentiation of small- and medium-size activated CD8+ cells from BRC ascites, in allogeneic activation, to Perf+ cells. Preferential differentiation of E75-TCR+CD8+Perf+ cells in distinct patients by AE-37 and AE-47 indicates that cancer vaccines will benefit from such correct individual and disease-associated help. Additional studies using the natural peptides p776 and F7 are needed to understand whether the LRMK-(Ava) tetra-, or pentamer augments or inhibits differentiation of CD8+ cells, compared with native, natural HER-2 peptides and/or protects CD8+ cells activated by E75 and by other HLA-I bound peptides from death. Our findings also develop a model for uniform quantification of differentiated CD8+ effectors. en
heal.journalName Anticancer Research en
dc.identifier.volume 29 en
dc.identifier.issue 7 en
dc.identifier.spage 2427 en
dc.identifier.epage 2435 en

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record